European Telephony Numbering Space

Barclays Announces Split of Certain iPath® ETNs

Retrieved on: 
Wednesday, May 19, 2021

Please contact Barclays for further questions:\nFinancial advisors: Directly contact Barclays at [email protected] or 1-212-528-7990 to obtain further information.\nIndividual investors: Instruct your broker/advisor/custodian to email us at [email protected] or call us at: 1-212-528-7990.

Key Points: 
  • Please contact Barclays for further questions:\nFinancial advisors: Directly contact Barclays at [email protected] or 1-212-528-7990 to obtain further information.\nIndividual investors: Instruct your broker/advisor/custodian to email us at [email protected] or call us at: 1-212-528-7990.
  • Barclays moves, lends, invests and protects money for customers and clients worldwide.\nFor further information about Barclays, please visit our website www.barclays.com\nAn investment in the iPath ETNs described herein involves risks.
  • As a result, the actual and perceived creditworthiness of Barclays Bank PLC will affect the market value, if any, of the ETNs prior to maturity or redemption.
  • iPath, iPath ETNs and the iPath logo are registered trademarks of Barclays Bank PLC.

UBS Declares Coupon Payments on 5 ETRACS Exchange Traded Notes

Retrieved on: 
Friday, May 7, 2021

The Current Yield is not indicative of future coupon payments, if any, on the ETN.

Key Points: 
  • The Current Yield is not indicative of future coupon payments, if any, on the ETN.
  • As such, the Current Yield for each is not indicative of future coupon payments, if any, on these ETNs.\nETRACS ETNs are senior unsecured notes issued by UBS AG, are traded on NYSE Arca, and can be bought and sold through a broker or financial advisor.
  • The applicable offering document for each ETRACS may be obtained by clicking on the name of each ETRACS identified above.
  • The key symbol, UBS and ETRACS are among the registered and unregistered trademarks of UBS.

UBS Announces Successor Index to the Wells Fargo Business Development Company Index

Retrieved on: 
Monday, April 26, 2021

UBS is not providing tax advice to holders of ETNs and such holders should consult with their tax advisors regarding the tax treatment of the ETNs.\nThe Wells Fargo Business Development Company Index is a float-adjusted, capitalization-weighted Index that is intended to measure the performance of all Business Development Companies (\xe2\x80\x9cBDC\xe2\x80\x9d) that are listed on the New York Stock Exchange (\xe2\x80\x9cNYSE AMEX\xe2\x80\x9d) or NASDAQ and satisfy specified market capitalization and other eligibility requirements.

Key Points: 
  • UBS is not providing tax advice to holders of ETNs and such holders should consult with their tax advisors regarding the tax treatment of the ETNs.\nThe Wells Fargo Business Development Company Index is a float-adjusted, capitalization-weighted Index that is intended to measure the performance of all Business Development Companies (\xe2\x80\x9cBDC\xe2\x80\x9d) that are listed on the New York Stock Exchange (\xe2\x80\x9cNYSE AMEX\xe2\x80\x9d) or NASDAQ and satisfy specified market capitalization and other eligibility requirements.
  • The Original Index was publicly disseminated starting from January 2011 and has no live performance history prior to that date.\nThe MVIS US Business Development Companies Index is a modified market cap-weighted index that tracks the performance of the largest and most liquid companies which are treated as Business Development Companies (BDC) and are incorporated in the United States.
  • The ETNs are not sponsored, endorsed, sold or promoted by Market Vectors Index Solutions GmbH (\xe2\x80\x9cLicensor\xe2\x80\x9d) and Licensor makes no representation or warranty, express or implied, to the owners of the ETNs or any member of the public regarding the advisability of investing in securities generally or in the ETNs particularly or the ability of the MVIS US Business Development Companies Index to track the performance of the US BDC market.\nWells Fargo Securities, Wells Fargo, and Wells Fargo Business Development Company Index are trademarks of Wells Fargo & Company and have been licensed for use for certain purposes by UBS.
  • The key symbol, UBS and ETRACS are among the registered and unregistered trademarks of UBS.

Barclays Bank PLC Announces Reverse Split of the iPath ® Series B S&P 500 ® VIX Short-Term Futures™ ETNs

Retrieved on: 
Friday, April 9, 2021

Barclays Bank PLC (Barclays) announced today that it will implement a 1 for 4 reverse split of its iPath Series B S&P 500 VIX Short-Term Futures ETNs (CUSIP: 06746P621) (the ETNs) which it intends to be effective at the open of trading on Friday, April 23, 2021.

Key Points: 
  • Barclays Bank PLC (Barclays) announced today that it will implement a 1 for 4 reverse split of its iPath Series B S&P 500 VIX Short-Term Futures ETNs (CUSIP: 06746P621) (the ETNs) which it intends to be effective at the open of trading on Friday, April 23, 2021.
  • Barclays is the issuer of iPath ETNs and Barclays Capital Inc. is the Issuers agent in the distribution.
  • S&P, S&P 500, and "S&P 500 VIX Short-Term Futures", and "S&P 500 Dynamic VIX Futures" are trademarks of Standard & Poors Financial Services LLC ("SPFS").
  • iPath, iPath ETNs and the iPath logo are registered trademarks of Barclays Bank PLC.

UBS Launches Seven New 2x Leveraged US Factor ETNs

Retrieved on: 
Wednesday, February 10, 2021

The Index is a total return index calculated by FTSE Russell and reinvests regular cash distributions across the Index.

Key Points: 
  • The Index is a total return index calculated by FTSE Russell and reinvests regular cash distributions across the Index.
  • This material is issued by UBS AG and/or any of its subsidiaries and/or any of its affiliates ("UBS").
  • The IWFL, IWML and IWDL ETNs (the ETNs) have been developed solely by UBS.
  • The key symbol, UBS and ETRACS are among the registered and unregistered trademarks of UBS.

NeuroSigma's Monarch eTNS for Pediatric ADHD Featured in MD+DI's List of the 10 Wearable Medical Devices that Redefined Healthcare

Retrieved on: 
Friday, December 18, 2020

NeuroSigma thanks MD+DI for its recognition of NeuroSigma's FDA cleared Monarch eTNS System for Pediatric ADHD in its list of the 10 FDA Cleared or Approved Wearable Medical Devices that Redefined Healthcare .

Key Points: 
  • NeuroSigma thanks MD+DI for its recognition of NeuroSigma's FDA cleared Monarch eTNS System for Pediatric ADHD in its list of the 10 FDA Cleared or Approved Wearable Medical Devices that Redefined Healthcare .
  • "NeuroSigma's Monarch eTNS System was the first non-drug treatment for pediatric ADHD cleared by the FDA.
  • This builds momentum for increased adoption and better awareness of the unique therapeutic advantages the Monarch eTNS System offers.
  • eTNS, Monarch, and Monarch eTNS are trademarks of NeuroSigma, Inc.
    For more information on eTNS, please visit the Monarch eTNS website .

UBS Announces Mandatory Redemption of Eleven Series A ETRACS ETNs and Suspends Further Sales of the Series A ETRACS ETNs

Retrieved on: 
Tuesday, November 3, 2020

In addition, UBS AG previously announced a waiver of the minimum early redemption size for each of these five Series A ETNs.

Key Points: 
  • In addition, UBS AG previously announced a waiver of the minimum early redemption size for each of these five Series A ETNs.
  • UBS AG has also announced the waiver of the minimum early redemption size for each of these six Series A ETNs.
  • Investors should always consult their financial advisors and compare the intraday indicative value of the Series A ETNs with the Series A ETNs then-prevailing market price before purchasing or selling the Series A ETNs, especially Series A ETNs with premium characteristics.
  • The key symbol, UBS and ETRACS are among the registered and unregistered trademarks of UBS.

NeuroSigma Announces Publication of ADHD Clinical Trial Data That Provide Additional eTNS Mechanism of Action

Retrieved on: 
Thursday, October 22, 2020

The paper presents results of research conducted at UCLA as part of the pivotal trial of external TNS (eTNS) for pediatric ADHD that supported NeuroSigma's FDA clearance of the Monarch eTNS System.

Key Points: 
  • The paper presents results of research conducted at UCLA as part of the pivotal trial of external TNS (eTNS) for pediatric ADHD that supported NeuroSigma's FDA clearance of the Monarch eTNS System.
  • "Specifically, the mechanism of action was demonstrated by the treatment-induced changes in frontal brain activity that showed a correlation with clinical outcome.
  • Functional neuroimaging data suggests the mechanism of action of TNS is related to its ability to modulate activity in targeted brain regions.
  • eTNS, Monarch, and Monarch eTNS are trademarks of NeuroSigma, Inc.
    For more information on eTNS, please visit the Monarch eTNS website .

Citigroup Announces the Acceleration of Ten Series of ETNs

Retrieved on: 
Monday, October 19, 2020

Holders of the ETNs will receive a cash payment per ETN in an amount (the Optional Acceleration Redemption Amount) equal to the fixing indicative value of the respective series of ETNs on the Optional Acceleration Valuation Date.

Key Points: 
  • Holders of the ETNs will receive a cash payment per ETN in an amount (the Optional Acceleration Redemption Amount) equal to the fixing indicative value of the respective series of ETNs on the Optional Acceleration Valuation Date.
  • The Optional Acceleration Valuation Date is expected to be October 30, 2020.
  • The Optional Acceleration Redemption Amount is expected to be paid to investors on November 4, 2020.
  • Currently, holders of any series of ETNs who wish to exercise their early redemption right are generally required to redeem a minimum number of ETNs of the same series and may be subject to an early redemption charge.

Citigroup Announces the Early Redemption of Three Series of C-Tracks ETNs

Retrieved on: 
Monday, October 19, 2020

Currently, holders of any series of C-Tracks ETNs who wish to exercise their early redemption right are generally required to redeem a minimum number of C-Tracks ETNs of the same series and may be subject to an early redemption charge.

Key Points: 
  • Currently, holders of any series of C-Tracks ETNs who wish to exercise their early redemption right are generally required to redeem a minimum number of C-Tracks ETNs of the same series and may be subject to an early redemption charge.
  • After the close of trading on October 19, 2020, Citigroup and CGMHI will irrevocably waive the required minimum redemption amount and the early redemption charge for the respective C-Tracks ETNs.
  • As described in the pricing supplements for DIVC and MLPC, Citigroup discontinued further issuances of DIVC and MLPC in 2015.
  • The amount paid upon redemption will be based on the closing indicative value of the ETNs and will not reflect any premium.